Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen partner Inspiration Biopharmaceuticals, has initiated treatment of patients in the first of two Phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A.
Subscribe to our email newsletter
Under the terms of their partnership agreement signed in January 2010, Inspiration in-licensed OBI-1 from Ipsen, and is responsible for the clinical development, regulatory process and commercialisation of the product.
In the context of this first phase III clinical study initiation, Ipsen has subscribed to a $50m newly issued convertible note by Inspiration, bringing its fully diluted share ownership position in Inspiration to about 34.0%.
Ipsen chairman and CEO Jean-Luc Belingard said that the initiation of this OBI-1 phase III clinical trial marks a milestone in the treatment of acquired hemophilia.